Search results
Showing 121 to 135 of 158 results for urinary tract infections
The NGAL Test for early diagnosis of acute kidney injury (MIB3)
NICE has developed a medtech innovation briefing (MIB) on the NGAL Test for early diagnosis of acute kidney injury .
Source guidance details Comes from guidance Urinary tract infection in under 16s: diagnosis and management...
Source guidance details Comes from guidance Urinary tract infection in under 16s: diagnosis and management...
Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)
Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults.
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.
This quality standard covers assessing and managing bedwetting (nocturnal enuresis) in children and young people (aged 18 and under). It describes high-quality care in priority areas for improvement.
View quality statements for QS70Show all sections
Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)
This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.
This quality standard covers managing urinary incontinence in women (aged 18 and over). It covers assessment, care and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS77Show all sections
Sections for QS77
- Quality statements
- Quality statement 1: Initial assessment
- Quality statement 2: Bladder diaries and lifestyle changes
- Quality statement 3: Containment products
- Quality statement 4: Supervised pelvic floor muscle training
- Quality statement 5: Bladder training
- Quality statement 6: Indwelling catheters
- Quality statement 7: Multidisciplinary team review before surgery or invasive treatment
UroShield for preventing catheter-associated urinary tract infections (MTG69)
We have moved Medical technologies guidance 69 to become HealthTech guidance 620. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
UroShield for preventing catheter-associated urinary tract infections (MIB191)
This advice has been updated and replaced by NICE healthtech guidance 620.
Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)
This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.
Urinary tract infection in under 16s: diagnosis and management (CG54)
This guidance has been updated and replaced by NICE guideline NG224.
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.